349 related articles for article (PubMed ID: 23936572)
1. Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity.
Messaoudi I; Vomaske J; Totonchy T; Kreklywich CN; Haberthur K; Springgay L; Brien JD; Diamond MS; Defilippis VR; Streblow DN
PLoS Negl Trop Dis; 2013; 7(7):e2343. PubMed ID: 23936572
[TBL] [Abstract][Full Text] [Related]
2. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
[TBL] [Abstract][Full Text] [Related]
3. Chikungunya Virus Evades Antiviral CD8
Davenport BJ; Bullock C; McCarthy MK; Hawman DW; Murphy KM; Kedl RM; Diamond MS; Morrison TE
J Virol; 2020 Apr; 94(9):. PubMed ID: 32102875
[TBL] [Abstract][Full Text] [Related]
4. Chikungunya Virus Exposure Partially Cross-Protects against Mayaro Virus Infection in Mice.
Fumagalli MJ; de Souza WM; de Castro-Jorge LA; de Carvalho RVH; Castro ÍA; de Almeida LGN; Consonni SR; Zamboni DS; Figueiredo LTM
J Virol; 2021 Nov; 95(23):e0112221. PubMed ID: 34549980
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques.
Broeckel R; Fox JM; Haese N; Kreklywich CN; Sukulpovi-Petty S; Legasse A; Smith PP; Denton M; Corvey C; Krishnan S; Colgin LMA; Ducore RM; Lewis AD; Axthelm MK; Mandron M; Cortez P; Rothblatt J; Rao E; Focken I; Carter K; Sapparapau G; Crowe JE; Diamond MS; Streblow DN
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005637. PubMed ID: 28628616
[TBL] [Abstract][Full Text] [Related]
6. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
[TBL] [Abstract][Full Text] [Related]
7. Serological correlates of immune protection conferred by Chikungunya virus infection.
Sheela PJ; Sumathy K
Acta Virol; 2013; 57(4):471-3. PubMed ID: 24294963
[TBL] [Abstract][Full Text] [Related]
8. Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus.
Vazeille M; Moutailler S; Coudrier D; Rousseaux C; Khun H; Huerre M; Thiria J; Dehecq JS; Fontenille D; Schuffenecker I; Despres P; Failloux AB
PLoS One; 2007 Nov; 2(11):e1168. PubMed ID: 18000540
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus.
Muthumani K; Lankaraman KM; Laddy DJ; Sundaram SG; Chung CW; Sako E; Wu L; Khan A; Sardesai N; Kim JJ; Vijayachari P; Weiner DB
Vaccine; 2008 Sep; 26(40):5128-34. PubMed ID: 18471943
[TBL] [Abstract][Full Text] [Related]
10. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.
Hawman DW; Stoermer KA; Montgomery SA; Pal P; Oko L; Diamond MS; Morrison TE
J Virol; 2013 Dec; 87(24):13878-88. PubMed ID: 24131709
[TBL] [Abstract][Full Text] [Related]
11. Infection of myofibers contributes to increased pathogenicity during infection with an epidemic strain of chikungunya virus.
Rohatgi A; Corbo JC; Monte K; Higgs S; Vanlandingham DL; Kardon G; Lenschow DJ
J Virol; 2014 Mar; 88(5):2414-25. PubMed ID: 24335291
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate.
Gardner CL; Burke CW; Higgs ST; Klimstra WB; Ryman KD
Virology; 2012 Apr; 425(2):103-12. PubMed ID: 22305131
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of Chikungunya virus acute infection in the Island of La Réunion during the 2005-2006 outbreak.
Staikowsky F; Talarmin F; Grivard P; Souab A; Schuffenecker I; Le Roux K; Lecuit M; Michault A
PLoS One; 2009 Oct; 4(10):e7603. PubMed ID: 19893613
[TBL] [Abstract][Full Text] [Related]
14. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.
Mallilankaraman K; Shedlock DJ; Bao H; Kawalekar OU; Fagone P; Ramanathan AA; Ferraro B; Stabenow J; Vijayachari P; Sundaram SG; Muruganandam N; Sarangan G; Srikanth P; Khan AS; Lewis MG; Kim JJ; Sardesai NY; Muthumani K; Weiner DB
PLoS Negl Trop Dis; 2011 Jan; 5(1):e928. PubMed ID: 21264351
[TBL] [Abstract][Full Text] [Related]
15. Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia.
Dupuis-Maguiraga L; Noret M; Brun S; Le Grand R; Gras G; Roques P
PLoS Negl Trop Dis; 2012; 6(3):e1446. PubMed ID: 22479654
[TBL] [Abstract][Full Text] [Related]
16. Caribbean and La Réunion Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology.
Teo TH; Her Z; Tan JJ; Lum FM; Lee WW; Chan YH; Ong RY; Kam YW; Leparc-Goffart I; Gallian P; Rénia L; de Lamballerie X; Ng LF
J Virol; 2015 Aug; 89(15):7955-69. PubMed ID: 25995257
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the Opal Stop Codon Attenuates Chikungunya Virus-Induced Arthritis and Pathology.
Jones JE; Long KM; Whitmore AC; Sanders W; Thurlow LR; Brown JA; Morrison CR; Vincent H; Peck KM; Browning C; Moorman N; Lim JK; Heise MT
mBio; 2017 Nov; 8(6):. PubMed ID: 29138302
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.
Chu H; Das SC; Fuchs JF; Suresh M; Weaver SC; Stinchcomb DT; Partidos CD; Osorio JE
Vaccine; 2013 Jul; 31(33):3353-60. PubMed ID: 23727003
[TBL] [Abstract][Full Text] [Related]
19. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease.
Couderc T; Chrétien F; Schilte C; Disson O; Brigitte M; Guivel-Benhassine F; Touret Y; Barau G; Cayet N; Schuffenecker I; Desprès P; Arenzana-Seisdedos F; Michault A; Albert ML; Lecuit M
PLoS Pathog; 2008 Feb; 4(2):e29. PubMed ID: 18282093
[TBL] [Abstract][Full Text] [Related]
20. Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection.
Kishishita N; Takeda N; Anuegoonpipat A; Anantapreecha S
J Clin Microbiol; 2013 May; 51(5):1389-95. PubMed ID: 23408687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
